SkinTE®would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved.SkinTE® is a first-in-class autologous ...
Wuxi, China, July 01, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BYAH) (“Park Ha Biological” or the “Company”) announced that it has formally filed a complete ...
The Thrive Grant by small-business funding and coaching platform Breva is offered on a rolling basis throughout the year. The winner receives a $5,000 grant. The coming application cycles close on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results